Important Safety Information

What is the most important information I should know about PLUVICTO?Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer.To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.PLUVICTO may cause serious side effects, including:<ul><li>Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:<ul><li>Tiredness or weakness</li><li>Pale skin</li><li>Shortness of breath</li><li>Bleeding or bruising more easily than normal or difficulty stopping bleeding</li><li>Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers  </li></ul></li><li>Kidney problems. Tell your doctor right away if you develop any new or worsening symptoms, including passing urine less often or passing much smaller amounts of urine than usual</li></ul>Before you receive PLUVICTO, tell your doctor if any of these apply to you:<ul><li>You have low level of blood cell counts (hemoglobin, white blood cell count, absolute neutrophil count, platelet count)</li><li>You have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty stopping bleeding, or frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (possible signs of myelosuppression)</li><li>You have or have had kidney problems</li><li>You have or have had any other type of cancer or treatment for cancer, as PLUVICTO contributes to your long-term cumulative radiation exposure</li><li>You are sexually active as:<ul><li>All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby</li><li>You should use effective contraception for intercourse during treatment with PLUVICTO and for 14 weeks after your last dose</li><li>PLUVICTO may cause temporary or permanent infertility</li></ul></li></ul>Before administration of PLUVICTO, you should drink plenty of water in order to urinate as often as possible during the first hours after administration.The most common side effects of PLUVICTO include:<ul><li>Tiredness</li><li>Dry mouth</li><li>Nausea</li><li>Low red blood cell count</li><li>Loss of appetite</li><li>Changes in bowel movements (constipation or diarrhea)</li><li>Vomiting</li><li>Low blood platelet count</li><li>Urinary tract infection</li><li>Weight loss</li><li>Abdominal pain</li></ul>These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a href="https://www.fda.gov/medwatch" target="_blank" data-show-disclaimer="false" rel="noopener" title="https://www.fda.gov/medwatch">www.fda.gov/medwatch</a>, or call <a href="tel:1-800-332-1088">1-800-FDA-1088</a>.Please see full <a href="https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf" target="_blank" data-show-disclaimer="false" rel="noopener">Prescribing Information</a>.

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:<ul><li>has spread to other parts of the body (metastatic), and</li><li>has already been treated with other anticancer treatments</li></ul>

Approved Use

What is the most important information I should know about PLUVICTO?Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...

Not to worry. You can head over to our homepage or check out some of our content.

We're sorry - you do not have access.

The URL may have been incorrectly typed or the page may have been moved, deleted, or incorporated into another part of the website.

The webpage you are looking for is unavailable.

We're sorry - it looks like there is an issue.

neutral_0

You are about to leave a Novartis site and continue to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation.

You are about to leave PLUVICTO.com

You are now being directed to another Novartis website.

Work Sans

Poppins

Change Indication

PLUVICTO® I Lutetium Lu 177 vipivotide tetraxetan

For additional help, including samples, please contact your Novartis representative

LEARN MORE ABOUT

PSMA+ metastatic castration-resistant prostate cancer

LEARN MORE ABOUT

Where to get treatment

Patient Video

How PLUVICTO Is Made

Understanding PLUVICTO

Important Safety Information

Approved Use